{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:16:24Z","timestamp":1793146584198,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ARIDGI20L0"],"award-info":[{"award-number":["ARIDGI20L0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HOGAN220"],"award-info":[{"award-number":["HOGAN220"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["AHARE21G0"],"award-info":[{"award-number":["AHARE21G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL122372"],"award-info":[{"award-number":["R01HL122372"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Macrophage dysfunction has been well-described in Cystic Fibrosis (CF) and may contribute to bacterial persistence in the lung. Whether CF macrophage dysfunction is related directly to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in macrophages or an indirect consequence of chronic inflammation and mucostasis is a subject of ongoing debate. CFTR modulators that restore CFTR function in epithelial cells improve global CF monocyte inflammatory responses but their direct effects on macrophages are less well understood. To address this knowledge gap, we measured phagocytosis, metabolism, and cytokine expression in response to a classical CF pathogen, Pseudomonas aeruginosa in monocyte-derived macrophages (MDM) isolated from CF F508del homozygous subjects and nonCF controls. Unexpectedly, we found that CFTR modulators enhanced phagocytosis in both CF and nonCF cohorts. CFTR triple modulators also inhibited MDM mitochondrial function, consistent with MDM activation. In contrast to studies in humans where CFTR modulators decreased serum inflammatory cytokine levels, modulators did not alter cytokine secretion in our system. Our studies therefore suggest modulator induced metabolic effects may promote bacterial clearance in both CF and\u00a0nonCF monocyte-derived macrophages.<\/jats:p>","DOI":"10.1038\/s41598-023-38300-9","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T10:02:19Z","timestamp":1690279339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages"],"prefix":"10.1038","volume":"13","author":[{"given":"Daniel S.","family":"Aridgides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"Mellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine L.","family":"Gwilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas L.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Ashare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"38300_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn, J. S. Cystic fibrosis. Lancet Lond. Engl. 388, 2519\u20132531 (2016).","journal-title":"Lancet Lond. Engl."},{"key":"38300_CR2","unstructured":"Patient Registry | Cystic Fibrosis Foundation. https:\/\/www.cff.org\/medical-professionals\/patient-registry."},{"key":"38300_CR3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202110-2249OC","author":"SY Graeber","year":"2021","unstructured":"Graeber, S. Y. et al. Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles. Am. J. Respir. Crit. Care Med. https:\/\/doi.org\/10.1164\/rccm.202110-2249OC (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38300_CR4","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman, H. G. M. et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial. Lancet Lond. Engl. 394, 1940\u20131948 (2019).","journal-title":"Lancet Lond. Engl."},{"key":"38300_CR5","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","volume":"195","author":"KB Hisert","year":"2017","unstructured":"Hisert, K. B. et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am. J. Respir. Crit. Care Med. 195, 1617\u20131628 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38300_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ppul.26261","volume":"58","author":"S Sheikh","year":"2023","unstructured":"Sheikh, S. et al. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis. Pediatr. Pulmonol. 58, 825\u2013833 (2023).","journal-title":"Pediatr. Pulmonol."},{"key":"38300_CR7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202102-0509OC","author":"ET Zemanick","year":"2021","unstructured":"Zemanick, E. T. et al. A phase 3 open-label study of ELX\/TEZ\/IVA in children 6 through 11 years of age with CF and at least one F508del allele. Am. J. Respir. Crit. Care Med. https:\/\/doi.org\/10.1164\/rccm.202102-0509OC (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38300_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jcf.2017.03.011","volume":"16","author":"AA Tarique","year":"2017","unstructured":"Tarique, A. A. et al. CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis. J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc. 16, 475\u2013482 (2017).","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"38300_CR9","doi-asserted-by":"publisher","first-page":"e11004","DOI":"10.1371\/journal.pone.0011004","volume":"5","author":"Y Xu","year":"2010","unstructured":"Xu, Y. et al. Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA. PLoS ONE 5, e11004 (2010).","journal-title":"PLoS ONE"},{"key":"38300_CR10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3389\/fimmu.2020.01871","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang, S. et al. Consequences of CRISPR-Cas9-mediated CFTR knockout in human macrophages. Front. Immunol. 11, 1871 (2020).","journal-title":"Front. Immunol."},{"key":"38300_CR11","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.22.23284619","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. Aberrant immune programming in neutrophils in cystic fibrosis. medRxiv https:\/\/doi.org\/10.1101\/2023.01.22.23284619 (2023).","journal-title":"medRxiv"},{"key":"38300_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccm.2015.11.010","volume":"37","author":"EM Bruscia","year":"2016","unstructured":"Bruscia, E. M. & Bonfield, T. L. Innate and adaptive immunity in cystic fibrosis. Clin. Chest Med. 37, 17\u201329 (2016).","journal-title":"Clin. Chest Med."},{"key":"38300_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1159\/000446825","volume":"8","author":"EM Bruscia","year":"2016","unstructured":"Bruscia, E. M. & Bonfield, T. L. Cystic fibrosis lung immunity: The role of the macrophage. J. Innate Immun. 8, 550\u2013563 (2016).","journal-title":"J. Innate Immun."},{"key":"38300_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1165\/rcmb.2015-0322LE","volume":"54","author":"KB Hisert","year":"2016","unstructured":"Hisert, K. B. et al. Ivacaftor-induced proteomic changes suggest monocyte defects may contribute to the pathogenesis of cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 54, 594\u2013597 (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"38300_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3389\/fphar.2020.01219","volume":"11","author":"KB Hisert","year":"2020","unstructured":"Hisert, K. B. et al. CFTR modulator therapy enhances peripheral blood monocyte contributions to immune responses in people with cystic fibrosis. Front. Pharmacol. 11, 1219 (2020).","journal-title":"Front. Pharmacol."},{"key":"38300_CR16","doi-asserted-by":"publisher","first-page":"2200725","DOI":"10.1183\/13993003.00725-2022","volume":"61","author":"L Cavinato","year":"2022","unstructured":"Cavinato, L. et al. Elexacaftor-Tezacaftor-Ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis. Eur. Respir. J. 61, 2200725. https:\/\/doi.org\/10.1183\/13993003.00725-2022 (2022).","journal-title":"Eur. Respir. J."},{"key":"38300_CR17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202106-1426OC","author":"C Gabillard-Lefort","year":"2022","unstructured":"Gabillard-Lefort, C. et al. Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. https:\/\/doi.org\/10.1164\/rccm.202106-1426OC (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38300_CR18","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00461.2017","author":"R Barnaby","year":"2017","unstructured":"Barnaby, R. et al. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa. Am. J. Physiol. Lung Cell. Mol. Physiol. https:\/\/doi.org\/10.1152\/ajplung.00461.2017 (2017).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"38300_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02861-2021","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.02861-2021 (2022).","journal-title":"Eur. Respir. J."},{"key":"38300_CR20","doi-asserted-by":"crossref","unstructured":"The 32nd annual north american cystic fibrosis conference, colorado convention center, Denver, Colorado October 18\u201320, 2018. Pediatr. Pulmonol. 53, S148\u2013S456 (2018).","DOI":"10.1002\/ppul.24152"},{"key":"38300_CR21","unstructured":"The 33rd annual north american cystic fibrosis conference, October 31-November 2, 2019. Pediatr. Pulmonol. 54, S155\u2013S480 (2019)."},{"key":"38300_CR22","doi-asserted-by":"crossref","unstructured":"The 34th annual north american cystic fibrosis conference, October 7\u201323, 2020. Pediatr. Pulmonol. 55 Suppl 2, S38\u2013S361 (2020).","DOI":"10.1002\/ppul.25089"},{"key":"38300_CR23","doi-asserted-by":"publisher","first-page":"10935","DOI":"10.1038\/s41598-020-67729-5","volume":"10","author":"HF Hazlett","year":"2020","unstructured":"Hazlett, H. F. et al. Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival. Sci. Rep. 10, 10935 (2020).","journal-title":"Sci. Rep."},{"key":"38300_CR24","doi-asserted-by":"publisher","first-page":"9624","DOI":"10.1038\/s41598-019-46045-7","volume":"9","author":"DS Aridgides","year":"2019","unstructured":"Aridgides, D. S. et al. Functional and metabolic impairment in cigarette smoke-exposed macrophages is tied to oxidative stress. Sci. Rep. 9, 9624 (2019).","journal-title":"Sci. Rep."},{"key":"38300_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1515\/cclm-2021-0724","volume":"60","author":"K Habler","year":"2022","unstructured":"Habler, K. et al. Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum. Clin. Chem. Lab. Med. 60, 82\u201391 (2022).","journal-title":"Clin. Chem. Lab. Med."},{"key":"38300_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","volume":"6","author":"A Tsai","year":"2020","unstructured":"Tsai, A. et al. Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor\/tezacaftor\/ivacaftor. Pulm. Ther. 6, 275\u2013286 (2020).","journal-title":"Pulm. Ther."},{"key":"38300_CR27","unstructured":"Downloadable Materials | TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor). https:\/\/www.trikaftahcp.com\/downloadable-materials."},{"key":"38300_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612\u20131620 (2018).","journal-title":"N. Engl. J. Med."},{"key":"38300_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bph.13365","volume":"173","author":"E Matthes","year":"2016","unstructured":"Matthes, E. et al. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor). Br. J. Pharmacol. 173, 459\u2013470 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"38300_CR30","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00034.2019","author":"SJ Bose","year":"2019","unstructured":"Bose, S. J. et al. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator (CFTR) potentiators of human and mouse F508del-CFTR. Am. J. Physiol. Lung Cell. Mol. Physiol. https:\/\/doi.org\/10.1152\/ajplung.00034.2019 (2019).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"38300_CR31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1124\/mol.118.112177","volume":"94","author":"S Chin","year":"2018","unstructured":"Chin, S. et al. Lipophilicity of the cystic fibrosis drug, ivacaftor (VX-770), and its destabilizing effect on the major CF-causing mutation: F508del. Mol. Pharmacol. 94, 917\u2013925 (2018).","journal-title":"Mol. Pharmacol."},{"key":"38300_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1365-2958.1998.01062.x","volume":"30","author":"GA O\u2019Toole","year":"1998","unstructured":"O\u2019Toole, G. A. & Kolter, R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30, 295\u2013304 (1998).","journal-title":"Mol. Microbiol."},{"issue":"4","key":"38300_CR33","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jcf.2020.10.006","volume":"20","author":"K Hamilton","year":"2020","unstructured":"Hamilton, K. et al. Defective immunometabolism pathways in cystic fibrosis macrophages. J. Cyst. Fibros. 20(4), 664\u2013672 (2020).","journal-title":"J. Cyst. Fibros."},{"key":"38300_CR34","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.celrep.2016.09.008","volume":"17","author":"J Van den Bossche","year":"2016","unstructured":"Van den Bossche, J. et al. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep. 17, 684\u2013696 (2016).","journal-title":"Cell Rep."},{"key":"38300_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.immuni.2016.09.016","volume":"45","author":"SC-C Huang","year":"2016","unstructured":"Huang, S.C.-C. et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity 45, 817\u2013830 (2016).","journal-title":"Immunity"},{"key":"38300_CR36","first-page":"420","volume":"5","author":"S Galv\u00e1n-Pe\u00f1a","year":"2014","unstructured":"Galv\u00e1n-Pe\u00f1a, S. & O\u2019Neill, L. A. J. Metabolic reprograming in macrophage polarization. Front. Immunol. 5, 420 (2014).","journal-title":"Front. Immunol."},{"key":"38300_CR37","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1128\/IAI.00144-10","volume":"78","author":"E Amiel","year":"2010","unstructured":"Amiel, E., Lovewell, R. R., O\u2019Toole, G. A., Hogan, D. A. & Berwin, B. Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression. Infect. Immun. 78, 2937\u20132945 (2010).","journal-title":"Infect. Immun."},{"key":"38300_CR38","doi-asserted-by":"publisher","first-page":"21700","DOI":"10.1038\/s41598-020-78817-x","volume":"10","author":"CL Shrestha","year":"2020","unstructured":"Shrestha, C. L. et al. (R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages. Sci. Rep. 10, 21700 (2020).","journal-title":"Sci. Rep."},{"key":"38300_CR39","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","volume":"8","author":"S Zhang","year":"2018","unstructured":"Zhang, S., Shrestha, C. L. & Kopp, B. T. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function. Sci. Rep. 8, 17066 (2018).","journal-title":"Sci. Rep."},{"key":"38300_CR40","doi-asserted-by":"publisher","first-page":"e54556","DOI":"10.7554\/eLife.54556","volume":"9","author":"HH Jarosz-Griffiths","year":"2020","unstructured":"Jarosz-Griffiths, H. H. et al. Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. Elife 9, e54556 (2020).","journal-title":"Elife"},{"key":"38300_CR41","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3389\/fimmu.2019.01789","volume":"10","author":"S Lara-Reyna","year":"2019","unstructured":"Lara-Reyna, S. et al. Metabolic reprograming of cystic fibrosis macrophages via the IRE1\u03b1 arm of the unfolded protein response results in exacerbated inflammation. Front. Immunol. 10, 1789 (2019).","journal-title":"Front. Immunol."},{"key":"38300_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10863-016-9663-y","volume":"48","author":"A Atlante","year":"2016","unstructured":"Atlante, A. et al. Characterization of mitochondrial function in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function. J. Bioenerg. Biomembr. 48, 197\u2013210 (2016).","journal-title":"J. Bioenerg. Biomembr."},{"key":"38300_CR43","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/nu10070836","volume":"10","author":"ML Kleme","year":"2018","unstructured":"Kleme, M. L. et al. CFTR deletion confers mitochondrial dysfunction and disrupts lipid homeostasis in intestinal epithelial cells. Nutrients 10, 836 (2018).","journal-title":"Nutrients"},{"key":"38300_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1124\/jpet.109.162032","volume":"333","author":"M Kelly","year":"2010","unstructured":"Kelly, M. et al. Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J. Pharmacol. Exp. Ther. 333, 60\u201369 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"38300_CR45","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2147\/COPD.S257474","volume":"15","author":"SM Rowe","year":"2020","unstructured":"Rowe, S. M. et al. Efficacy and safety of the CFTR potentiator icenticaftor (QBW251) in COPD: Results from a phase 2 randomized trial. Int. J. Chron. Obstruct. Pulmon. Dis. 15, 2399\u20132409 (2020).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"38300_CR46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.coph.2017.09.013","volume":"34","author":"GM Solomon","year":"2017","unstructured":"Solomon, G. M., Fu, L., Rowe, S. M. & Collawn, J. F. The therapeutic potential of CFTR modulators for COPD and other airway diseases. Curr. Opin. Pharmacol. 34, 132\u2013139 (2017).","journal-title":"Curr. Opin. Pharmacol."},{"key":"38300_CR47","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S2213-2600(16)30047-9","volume":"4","author":"GM Solomon","year":"2016","unstructured":"Solomon, G. M. et al. Pilot evaluation of ivacaftor for chronic bronchitis. Lancet Respir. Med. 4, e32-33 (2016).","journal-title":"Lancet Respir. Med."},{"key":"38300_CR48","doi-asserted-by":"publisher","first-page":"eaav4634","DOI":"10.1126\/scitranslmed.aav4634","volume":"11","author":"SA Riquelme","year":"2019","unstructured":"Riquelme, S. A. et al. CFTR-PTEN-dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection. Sci. Transl. Med. 11, eaav4634 (2019).","journal-title":"Sci. Transl. Med."},{"key":"38300_CR49","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201905-1013OC","author":"OJ McElvaney","year":"2019","unstructured":"McElvaney, O. J. et al. Specific inhibition of the NLRP3 inflammasome as an anti-inflammatory strategy in cystic fibrosis. Am. J. Respir. Crit. Care Med. https:\/\/doi.org\/10.1164\/rccm.201905-1013OC (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38300_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1099\/00222615-4-2-263","volume":"4","author":"AV Armstrong","year":"1971","unstructured":"Armstrong, A. V. & Stewart-Tull, D. E. The site of the activity of extracellular products of Pseudomonas aeruginosa in the electron-transport chain in mammalian cell respiration. J. Med. Microbiol. 4, 263\u2013270 (1971).","journal-title":"J. Med. Microbiol."},{"key":"38300_CR51","doi-asserted-by":"publisher","first-page":"e12787","DOI":"10.1111\/cmi.12787","volume":"20","author":"AM Neely","year":"2018","unstructured":"Neely, A. M. et al. N-(3-Oxo-acyl)-homoserine lactone induces apoptosis primarily through a mitochondrial pathway in fibroblasts. Cell. Microbiol. 20, e12787 (2018).","journal-title":"Cell. Microbiol."},{"key":"38300_CR52","doi-asserted-by":"publisher","first-page":"11929","DOI":"10.1038\/s41598-019-47457-1","volume":"9","author":"NM Maurice","year":"2019","unstructured":"Maurice, N. M. et al. Pseudomonas aeruginosa induced host epithelial cell mitochondrial dysfunction. Sci. Rep. 9, 11929 (2019).","journal-title":"Sci. Rep."},{"key":"38300_CR53","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1096\/fba.2019-00084","volume":"2","author":"B Rieger","year":"2020","unstructured":"Rieger, B. et al. Pseudomonas quinolone signal molecule PQS behaves like a B class inhibitor at the IQ site of mitochondrial complex I. FASEB BioAdvances 2, 188\u2013202 (2020).","journal-title":"FASEB BioAdvances"},{"key":"38300_CR54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.it.2017.03.001","volume":"38","author":"J Van den Bossche","year":"2017","unstructured":"Van den Bossche, J., O\u2019Neill, L. A. & Menon, D. Macrophage immunometabolism: Where are we (Going)?. Trends Immunol. 38, 395\u2013406 (2017).","journal-title":"Trends Immunol."},{"key":"38300_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","volume":"1038","author":"EK Schneider","year":"2016","unstructured":"Schneider, E. K. et al. Development of HPLC and LC-MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1038, 57\u201362 (2016).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"38300_CR56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/FTD.0000000000000829","volume":"43","author":"SEM Vonk","year":"2021","unstructured":"Vonk, S. E. M. et al. Quantitative method for the analysis of ivacaftor, hydroxymethyl ivacaftor, ivacaftor carboxylate, lumacaftor, and tezacaftor in plasma and sputum using liquid chromatography with tandem mass spectrometry and its clinical applicability. Ther. Drug Monit. 43, 555\u2013563 (2021).","journal-title":"Ther. Drug Monit."},{"key":"38300_CR57","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-1989OC","author":"KJ Mould","year":"2020","unstructured":"Mould, K. J. et al. Airspace macrophages and monocytes exist in transcriptionally distinct subsets in healthy adults. Am. J. Respir. Crit. Care Med. https:\/\/doi.org\/10.1164\/rccm.202005-1989OC (2020).","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38300-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T10:09:15Z","timestamp":1690279755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38300-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38300"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38300-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11995"}}